None ...

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the ...

Key Points Interested in Revolution Medicines, Inc.? Here are five stocks we like better. Daraxonrasib moved closer to ...

U.S. FDA accepted daraxonrasib New Drug Application for review for previously treated metastatic pancreatic cancer following unprecedented Phase ...

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A ...

Rigel reported net income of $17.3 million, or $0.93 basic and $0.88 diluted per share, compared to $59.6 million, or $3.33 basic and $3.28 diluted per share, for the same period of 2025. As noted ...

The Cancer Color Celebration will be held Thursday, Aug. 13 at the Fergus County Trade Center from 6-9 p.m. This is a ...

Since 1968, The Enquirer has honored women who have made Greater Cincinnati a better place through leadership, philanthropy ...

Q2 2026 Earnings Call July 30, 2026 4:30 PM EDTCompany ParticipantsZarak Khurshid - Vice President of Investor ...

The firm increased its full-year guidance to a new range of $1.34 billion to 1.36 billion from a previous range of $1.30 billion to $1.32 billion.

Colorectal cancer screening in America faces a critical paradox: while early detection dramatically improves survival rates, millions of eligible patients remain unscreened due to barriers ranging ...